Sinocare Unveils Advanced Diabetes Management Tools at EASD 2025

The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) took place in Vienna, Austria, revealing significant advancements in diabetes management from Sinocare. Held on October 15, 2025, the event featured a series of presentations and an international symposium that demonstrated Sinocare's commitment to enhancing clinical practices and patient care through innovative technology.

Expert Insights at the Symposium

The opening day of EASD 2025 showcased enlightening insights from renowned experts in the diabetes field. Professor Lori Laffel, Dr. Guido Freckmann, and Professor Julia Mader shared research about the iCan™ Continuous Glucose Monitor (CGM). The symposium emphasized three crucial aspects—performance, practicality, and pediatrics—highlighting findings from recent studies conducted in Germany and the U.S. involving both adult and pediatric populations.

The implications of CGM technology on various life factors—including travel and job prospects for individuals with diabetes who aspire to fly—also emerged as significant discussion points. The experts asserted that this technology facilitates better management and enhances the quality of life for patients.

Launch of the iCan i6 CGM

A star attraction at Sinocare's booth was the next-generation iCan i6 CGM system. This cutting-edge monitor boasts impressive accuracy over a 15-day period and is designed for user comfort. Key improvements include a smaller, lighter sensor, a one-step application process, and enhanced support in 27 languages, ensuring widespread global accessibility.

Additionally, the iCan i6 features a built-in altitude compensation algorithm that ensures reliable readings even at high elevations. Attendees also noted the improved mobile app integration, which simplifies monitoring practices and enhances user interaction with the device.

Sinocare's collaboration with A. Menarini Diagnostics s.r.l. resulted in the co-branded GlucoMen® iCan CGM system, which was presented at EASD in an engaging booth experience. Medical professionals at the conference expressed significant interest in the latest features and clinical benefits presented by Menarini.

A New Diabetes Prevention and Control Ecosystem

On September 15, Sinocare introduced its "A+C" Diabetes Prevention and Control Ecosystem during a private dinner seminar for key partners. This innovative model integrates AGEscan, a non-invasive screening tool with CGM technology. Such integration allows for precise early risk detection and the opportunity for timely intervention in diabetes management.

Furthermore, Sinocare unveiled a hospital glucose management solution that connects outpatient and inpatient scenarios seamlessly, delivering comprehensive digital diabetes management. This initiative aims to enhance efficiency and improve the overall quality of healthcare services provided to diabetic patients.

Conclusion

Sinocare's presence at EASD 2025 underscores its commitment to merging technological innovation with patient-centered care. Through collaboration with global experts and partners, the company illustrates its role as a leader in the diabetes management sector, showcasing advancements that promise to enhance patient outcomes across the globe.